Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
29 août 2023 05h00 HE
|
F. Hoffmann-La Roche Ltd
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more...
European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
29 août 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1Approval is based on interim data from ongoing RAINBOWFISH trial showing majority of...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
23 août 2023 01h22 HE
|
F. Hoffmann-La Roche Ltd
Basel, 23 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study,...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten
27 juil. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 27. Juli 2023 Verkäufe der Roche-Gruppe ohne COVID-19-Produkte steigen deutlich um 8%1 zu konstanten Wechselkursen (CER) Durch die erwartungsgemäss rückläufige Nachfrage nach...
[Annonce événementielle au sens de l’art. 53 RC] Roche fait état d’une forte croissance de son activité de base dans ses deux divisions ; les ventes et le bénéfice du groupe reflètent la baisse des ventes de produits liés au COVID-19
27 juil. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Bâle, le 27 juillet 2023 Sans les produits liés au COVID-19, le chiffre d’affaires consolidé a fortement augmenté de 8 %1 à taux de change constants (TCC) Conformément à la baisse de la demande...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products
27 juil. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Basel, 27 July 2023 Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER) In line with the expected declining demand for COVID-19 products, Group sales...
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
24 juil. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Partnership combines Roche’s proven track record of successfully developing and launching innovative medicines worldwide with Alnylam’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi...
CHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
21 juil. 2023 09h30 HE
|
F. Hoffmann-La Roche Ltd
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority of Evrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies...
New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
20 juil. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME)Real-world data reinforce that...
Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
13 juil. 2023 01h00 HE
|
F. Hoffmann-La Roche Ltd
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS...